Kidney Week 2025 Annual Meeting-Late-Breaking Research Orals

Video Transcription

Video Summary

This late-breaking oral session featured multiple kidney- and immunology-focused clinical updates.<br /><br />A preliminary pediatric study from Shenzhen University evaluated off-the-shelf anti-CD19/BCMA CAR-NK therapy in 11 children with refractory systemic lupus erythematosus (SLE). After lymphodepletion and weight-based infusion, circulating CD19+ B cells were rapidly depleted within 7 days and recovered by 2–3 months. Complement C3 and anti-dsDNA improved toward normal, lupus nephritis parameters and physician/patient global assessments improved within 1–3 months, and SLEDAI scores fell. Safety was favorable: two mild cytokine release syndrome cases, no neurotoxicity, and other adverse events/infections were mild and manageable.<br /><br />A Phase 1B randomized, placebo-controlled multiple-ascending-dose trial of faribursen (anti–miR-17 oligonucleotide) in autosomal dominant polycystic kidney disease showed dose-dependent increases in urinary exosomal polycystin-1 and -2 and an apparent dose-related slowing of height-adjusted total kidney volume growth over ~4 months (pooled higher-dose groups ~0% vs placebo +2.7%). Main adverse events were mild injection-site reactions; some mild/moderate transaminase elevations occurred without bilirubin increases.<br /><br />The TCHVET trial in U.S. veterans tested comprehensive pre-ESKD kidney replacement therapy (KRT) education (COPE) versus enhanced usual care. Most patients were initially unsure of modality; both arms improved decisional state, but COPE produced dramatically higher odds of high-quality modality choice and greater KRT knowledge.<br /><br />RUBY-3 reported povetacicept (BAFF/APRIL “sink”) at 48 weeks. In IgA nephropathy, proteinuria fell ~64%, hematuria largely resolved, and Gd-IgA1 decreased ~77% with stable eGFR. In primary membranous nephropathy, proteinuria fell ~82%, anti-PLA2R dropped ~83%, and immunologic remission reached 100% by week 48; safety was generally mild.<br /><br />TESTING-ON long-term follow-up suggested oral methylprednisolone’s kidney-protective effect in IgA nephropathy persisted (HR ~0.67), largely driven by early benefit, though long-term adverse events and post-trial treatments were incompletely captured.<br /><br />Finally, the 2025 AHA/ACC hypertension guideline update emphasized CKD as a risk equivalent prompting treatment at ≥130/80, endorsed ACEi/ARB strongly in diabetic CKD, retained BP targets <130/80 (vs KDIGO <120), and noted limited transplant-specific evidence.

Asset Subtitle

Moderator(s): Krzysztof Kiryluk, Laura Mariani

Presentation(s):

Safety and Efficacy of Anti-CD19/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor-Natural Killer Cell (CAR-NK) Therapy in Pediatric Patients with Refractory Systemic Lupus Erythematosus (SLE): A Preliminary Clinical Study - Hanyan Meng
Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD - Alan Yu
Trial to Evaluate and Assess Effects of Comprehensive Kidney Replacement Therapy (KRT)-Directed, Pre-ESKD Education (CoPE) on Home Dialysis Among Veterans (TEACH-VET): Evaluating KRT Decision-Making State (KDS) Outcomes - Ashutosh Shukla
Efficacy and Safety of Povetacicept in Patients with IgAN and Primary Membranous Nephropathy (pMN) at 48 Weeks of Treatment: The RUBY-3 Study - James Tumlin
Long-Term Effect of Oral Methylprednisolone on Kidney Outcomes in Patients with IgAN: TESTING-ON, a Post-Trial Observational Study - Muh Geot Wong
AHA/ACC Hypertension Guidelines: What's New for Kidney Diseases? - Vivek Bhalla

Note: Continuing education credits are not being offered for this session.

Meta Tag

Date 11/8/2025

Pathway 1 Other

Session ID 527930

Keywords

CAR-NK therapy

anti-CD19/BCMA

pediatric systemic lupus erythematosus

lupus nephritis

faribursen

anti–miR-17 oligonucleotide

autosomal dominant polycystic kidney disease

kidney replacement therapy education (COPE)

povetacicept (BAFF/APRIL inhibitor)

IgA nephropathy

2025 AHA/ACC hypertension guideline CKD